
The approval makes Gazyva the first FDA-approved treatment for the kidney disease, based on a phase III trial against tacrolimus.
The FDA approved Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy at risk of disease progression. Roche said it is the first treatment approved by the agency for the condition.
The decision was based on the phase III MAJESTY trial. At two years, 36.1% of patients receiving Gazyva achieved complete remission of proteinuria, compared with 5.7% of those receiving tacrolimus.
The trial also found higher overall remission at week 104 with Gazyva than with tacrolimus, at 50% versus 12.9%. Roche said the drug’s safety results matched its established profile, with no new safety signals identified.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.